Chinese Vitamin C manufacturers found liable for price fixing in the United States -- court orders total damages of US$162 million - Case is a wakeup call for foreign companies doing business in the United States

by DLA Piper
Contact

In a case that reverberated throughout Chinese state-owned and private companies, as well as various organs of the Chinese government, in a recent private civil class action case in United States District Court for the Eastern District of New York, a jury found the remaining defendants liable for fixing the prices and limiting the supply of vitamin C exported to the United States from China 1. The jury rejected the defense argument that they should not be held liable because their agreement was compelled by the Chinese government. The jury awarded damages of US$54 million and the court, according to American law, tripled this amount to US$162 million. While this represents a substantial jury verdict, it is relatively small compared to other private class action cartel verdicts recently entered by United States courts.

The Vitamin C case

Cartel cases like the Vitamin C case are usually brought as “class actions.” A class action allows individual plaintiffs whose overcharge claims might be too small to warrant the expense of filing a suit, to join together in one suit where the collective overcharges may be significant. A court may certify a class of hundreds, or even thousands, of individual plaintiffs in one lawsuit when common questions of law or fact predominate over any questions affecting only individual class members. In a cartel case, the main questions at trial will be common to all plaintiffs: was there a cartel; and, if so, by how much did it raise prices? If a jury renders a damage verdict for the plaintiffs, individual class members are allotted a share of the damages based on how much of the product in question they purchased. If a single customer purchased a very large amount of the product that was subject to the cartel, they may “opt-out” of the class action suit. An opt-out plaintiff withdraws from the class action to pursue a case on their own. Cartel cases are attractive to private plaintiffs because the amount of damages found by the jury is tripled.

The plaintiffs in the Vitamin C case were American food and beverage companies, vitamin packagers, and wholesalers and distributors who purchased vitamin C manufactured in China and shipped into the United States. The defendants were HeBei Welcome Pharmaceutical Co. Ltd; Aland (Jiangsu) Nutraceutical Co. Ltd.; Northeast Pharmaceutical Co. Ltd; and Weisheng Pharmaceutical Co. Ltd. The lawsuit alleged that customers who purchased imported vitamin C from the defendants had been overcharged as a result of an illegal cartel to fix prices and limit supply. Aland (Jiangsu) and Weisheng settled their case before trial by agreeing to pay monetary damages. HeBei and its parent, North China Pharmaceutical, went to trial.

Pretrial motions

The Chinese government compelled the collective conduct

Before a case proceeds to trial the defense may file motions to attempt to have the case dismissed. In this case, the defendants did not deny that they had fixed prices, but claimed they should not be held liable because the Chinese government compelled their conduct. This defense, known as foreign sovereign compulsion, recognizes that a foreign national should not be faced with the dilemma of violating its own native law to comply with American law. This defense, however, is difficult to prove as courts and juries in the United States are often skeptical that a government would “force” companies to fix prices. Defendants also raised two related defenses pretrial: comity and state action. Under the doctrine of comity, a court may refrain from hearing a case if doing so would unduly infringe on the laws or actions of another country. Comity is optional on the part of the prosecution and the Court as it is generally governed by equitable law in the United States, rather than by statute or case law. The state action doctrine provides a defense if the evidence demonstrates that the government actually set and regulated, or actively supervised, the defendants’ prices. To be successful, each of these defenses required evidence of specific actions by the Chinese government or specific Chinese laws that compelled the defendants to fix the export price of vitamin C.

In support of defendants’ pretrial motions, the Ministry of Commerce of the People’s Republic of China (MOFCOM) filed a brief that explained the Chinese government’s regulation of vitamin C exports and the oversight of the Chamber of Commerce of Medicines and Health Products Importers and Exporters (the Chamber). The brief explained that MOFCOM “formulates strategies, guidelines and policies concerning domestic and foreign trade and international economic cooperation…and regulates market operation to achieve an integrated, competitive and orderly market system.” 2 In its brief, MOFCOM also explained that in China, regulations are not always clearly written, but there is a long history of a “system of self-discipline” that is well known to, and complied with, by Chinese companies. According to MOFCOM, the defendants understood that they were required to coordinate pricing or be subjected to sanctions, including revocation of the license to export. 3 MOFCOM’s brief asserted that defendants’ actions were compelled by the Chinese government.

The plaintiffs presented the court with a much different story. They pointed to evidence, mostly minutes from the vitamin C subcommittee of the Chamber, 4 which indicated that the agreements reached at the trade association were done so voluntarily. There was no evidence in the meeting minutes to support the idea that the defendants were compelled to fix prices. In addition, the 2002 Charter of the vitamin C subcommittee describes the subcommittee as “a self-disciplinary industry organization…established on a voluntary basis.” 5 The court also considered a filing made by the Chinese government to the World Trade Organization which stated that it gave up export administration of vitamin C as of January, 2002. 6 The court denied the motion to dismiss the case based on the foreign sovereign compulsion defense. Instead, the court concluded that “the Ministry’s [MOFCOM’s] assertion of compulsion is a post-hoc attempt to shield defendants’ conduct from antitrust scrutiny.” 7

The court did not have jurisdiction over activity in China

Another issue that was decided in the Vitamin C case before the case went to the jury is whether the court in the United States had jurisdiction to hear the case since all of the cartel activity took place in China. The United States does not want its courts burdened with cases involving foreign conduct which has only a minimal impact on American consumers. The United States Congress passed the Foreign Trade Antitrust Improvement Act of 1982 (FTAIA) that sets forth a general rule that the Sherman Act (the statute prohibiting cartels) “shall not apply to conduct involving trade or commerce (other than import trade or commerce) with foreign nations.” 8 As exceptions to the general rule against jurisdiction, the Act specifically provides jurisdiction where the cartel involves import commerce. The FTAIA also provides jurisdiction where the cartel has a “direct, substantial, and reasonably foreseeable effect” on commerce in the United States.

The facts in the Vitamin C case provided the court with jurisdiction on both of these grounds. First, most of the vitamin C sold by the defendants was imported commerce—that is, the product was sold by the defendants directly to customers in the United States. Secondly, even in instances where the vitamin C was first sold to a third party outside the United States (for example, a distributor) and then imported into the United States, the cartel still had a direct, substantial and reasonably foreseeable effect on commerce in the United States. The evidence showed that the defendants’ price fixing specifically targeted customers in the United States. This is sufficient to establish jurisdiction in the United States even if there is a third party intermediary before the sale is made in the United States. By contrast, there would likely not be jurisdiction in American court if the cartel had only fixed prices in Asia, even though arguably, prices in the United States might be indirectly raised because world markets are often interconnected. 9 

The court denied all of the defendants’ motions to have the case dismissed and the case went to trial.

The jury trial

The jury trial focused on the same issue of whether the defendants’ price fixing was compelled under Chinese law. The defendants called as a witness Qiao Haili, who headed the Chamber’s vitamin C subcommittee from 1997 to 2007. He testified that on behalf of MOFCOM, he compelled the companies to agree to prices and output. The witness further testified that he had the power to sanction companies that did not comply. The defendants called other witnesses who also asserted that the cooperation on export prices was compelled by MOFCOM. But, the defense witnesses had no contemporaneous documents to corroborate their claims of compulsion by Chinese law or involvement by the Chinese government in setting prices. The plaintiffs, on the other hand, presented to the jury the same type of evidence that had persuaded the judge in pretrial motions. For example, the subcommittee minutes contained no reference to compulsion or direction by the Chinese government. Instead, the documents indicated that the pricing agreements were reached voluntarily through “friendly consultation.” And, there was no evidence in any documents to indicate that companies might face sanctions if they did not reach agreement or failed to abide by the agreement. As usually happens in American court, the fact finder found that the contemporaneous documents created during the cartel period were more persuasive than the uncorroborated “after the fact” trial testimony of the defense witnesses. The jury found that there was a cartel, that it was not compelled by the Chinese government and awarded damages to the plaintiff.

The last word?

Following the verdict and judgment, the remaining defendants filed a Motion for Judgment as a Matter of Law, arguing that irrespective of the jury’s verdict, their conduct in China was mandated by the Chinese government and thus legal as a matter of law. Defendants pleadings make both legal arguments well as raise issues of foreign relations, including a lengthy recitation of MOFCOM’s press release criticizing the verdict and judgment as “totally improper” and warning that “[i]f such mistakes are not corrected, it will be worrisome for the global society and companies, which will lead to increasing international disputes and eventually harm US interests.” 10 If the trial court rejects defendants’ post-trial motions, defendants will no doubt file an appeal, where the appellate court can review completely the legal determinations of the trial court while giving substantial deference to its factual determinations.

A look ahead

The success of the plaintiffs in the Vitamin C case will no doubt encourage similar lawsuits by American customers of imported Chinese goods. Similar class action price fixing cases are already pending against Chinese bauxite and magnesium companies. There is also a civil case filed against Chinese manufacturers of solar panels alleging that those manufacturers colluded to sell at below cost prices in the United States to illegally disadvantage US companies. The ability to obtain evidence can present problems in bringing these lawsuits, but these problems are not insurmountable. The amount of Chinese goods imported into the United States and the lure of triple damages will likely lead to much more civil litigation. It is important that foreign companies that import product into the United States discuss possible competition issues with counsel early on and take corrective measures before becoming the target of a class action.

1 Two of the original defendants settled prior to trial.

2 In re Vitamin C Antitrust Litigation, 810 F. Supp. 2d 522, 525 (E.D.N.Y. 2011) (quoting the amicus brief filed by MOFCOM).

3 Id. at 533.

4 The minutes were posted on the Chamber’s public website, so they were available to the plaintiffs as evidence.

5 In re Vitamin C Antitrust Litigation, 810 F. Supp. at 530.

6 Id. at 532.

7 Id at 552. The court noted that if there was any compulsion at all, it was limited to setting prices at levels that would have avoided anti-dumping suits. Setting prices above that level exceeded the scope of any compulsion. Id. at 560.

8 15 United States Code Section 6(a)

9 Another very recent example where the FTAIA barred an antitrust suit from being brought in US court is Lotes v. Foxconn, 12 Civ. 7465 (S.D.N.Y. May 14, 2013). The plaintiff, Lotes, alleged that Foxconn had attempted to monopolize China’s USB connector industry through abuse of patent licensing. Even though all the alleged activity occurred in China, the plaintiff filed suit in United States federal court alleging that Foxconn’s action resulted in inflated prices for American consumer for USB connectors. The court dismissed the suit for lack of jurisdiction stating: “To the extent that defendants’ foreign anti-competitive conduct may result in higher prices and less competition here in the US, those effects are simply too attenuated to establish the proximate causation required by the FTAIA.”

10 Defendants’ Reply in Support of their Renewed Motion for Judgment as a Matter of Law (filed May 31, 2013), citing MOFCOM, "Regular Press Conference of the Ministry of Commerce [of the People’s Republic of China] on March 19, 2013," at 6-7, March 28, 2013, available at
http://english.mofcom.gov.cn/article/newsrelease/press/201304/20130400081992.shtml.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© DLA Piper | Attorney Advertising

Written by:

DLA Piper
Contact
more
less

DLA Piper on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.